Infection

, Volume 21, Issue 5, pp 297–302 | Cite as

Specific IgG2 antibodies toPseudomonas aeruginosa lipid A and lipopolysaccharide are early markers of chronic infection in patients with cystic fibrosis

  • Gitte Kronborg
  • T. Pressler
  • A. Fomsgaard
  • C. Koch
  • N. Høiby
Originalia
Received:
Accepted:

Summary

The IgG subclass antibody response to the two parts ofPseudomonas aeruginosa lipopolysaccharide; endotoxic lipid A and the O-polysaccharide, were investigated in a retrospective longitudinal study involving 16 patients with cystic fibrosis and chronicP. aeruginosa lung infection. The purpose of the study was to see if any of the IgG subclasses of either specificity could be used as prognostic markers in the development and subsequent course of the lung disease. IgG2 anti-lipid A, IgG3 anti-lipid A, and IgG2 anti-polysaccharide showed a significant positive correlation with deteriorating pulmonary function already before chronicP. aeruginosa lung infection was diagnosed as well as in subsequent years. The findings suggest antigenic exposure of the patient before chronic infection is detected by routine sputum examinations, and further support our previous findings of a critical role of the IgG subclass response in modulating the course of inflammatory lung damage in these patients.

Keywords

Cystic Fibrosis Lung Infection Specific IgG2 Antigenic Exposure Specific IgG2 Antibody 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Spezifische IgG2 Antikörper von Pseudomonas aeruginosa — Lipid A und Lipopolysaccharide sind frühzeitige Marker einer chronischen Infektion bei Patienten mit Cystischer Fibrose

Zusammenfassung

In einer retrospektiven longitudinalen Studie wurde bei 16 Patienten mit zystischer Fibrose und chronischer Lungeninfektion durchPseudomonas aeruginosa die IgG-Subklassen-Antikörperreaktion auf die beiden Anteile desP. aeruginosa-Lipopolysaccharids, das Endotoxin Lipoid A und O-Polysaccharid, untersucht. Dabei sollte geprüft werden, ob sich aus der spezifischen Antikörperantwort einer der IgG-Subklassen prognostische Marker für die Entwicklung und den weiteren Verlauf der Lungenerkrankung ableiten lassen. Eine positive Korrelation mit einer Verschlechterung der Lungenfunktion zeigte sich für anti-Lipoid A-IgG2- und IgG3-und anti-Polysaccharid IgG2-Antikörper schon bevor die chronischeP. aeruginosa-Infektion der Lunge diagnostiziert wurde und auch in den nachfolgenden Jahren. Diese Befunde lassen darauf schließen, daß es schon vor dem Nachweis der chronischen Infektion in Routine-Sputumuntersuchungen zu einer Antigenexposition kommt. Sie bestätigen frühere Studien, in denen wir feststellen konnten, daß die IgG-Subklassen-Reaktion in kritischer Weise den Verlauf der entzündlichen Lungenschädigung bei diesen Patienten mitbestimmt.

This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Pedersen, S. S. Lung infection with alginate-producing, mucoidPseudomonas aeruginosa in cystic fibrosis. APMIS 100 (Suppl. 28) (1992) 7–79.Google Scholar
  2. 2.
    Pressler, T., Pedersen, S. S., Espersen, F., Høiby, N., Koch, C. IgG subclass antibodies toPseudomonas aeruginosa in sera from patients with chronicPs. aeruginosa infection investigated by ELISA. Clin. Exp. Immunol. 81 (1990) 428–434.Google Scholar
  3. 3.
    Moss, R. B., Hsu, Y-P., Lewiston, N. J., Curd, J. G., Milgrom, H., Hart, S., Dyer, B., Larrick, J. W. Association of systemic immune complexes, complement activation, and antibodies toPseudomonas aeruginosa lipopolysaccharide and exotoxin A with mortality in cystic fibrosis. Am. Rev. Respir. Dis. 133 (1986) 648–652.Google Scholar
  4. 4.
    Fomsgaard, A., Dinesen, B., Shand, G. H., Pressler, T., Høiby, N. Antilipopolysaccharide antibodies and differential diagnosis of chronicPseudomonas aeruginosa lung infection in cystic fibrosis. J. Clin. Microbiol. 27 (1989) 1222–1229.Google Scholar
  5. 5.
    Kronborg, G., Fomsgaard, A., Galanos, C., Freudenberg, M. A., Høiby, N. Antibody responses to lipid A, core, and O sugars of thePseudomonas aeruginosa lipopolysaccharide in chronically infected cystic fibrosis patients. J. Clin. Microbiol. 30 (1992) 1848–1855.Google Scholar
  6. 6.
    Kronborg, G., Shand, G. H., Fomsgaard, A., Høiby, N. Lipopolysaccharide is present in immune complexes isolated from sputum in patients with cystic fibrosis and chronicPseudomonas aeruginosa lung infection. APMIS 100 (1992) 175–180.Google Scholar
  7. 7.
    Pressler, T., Pandey, J. P., Espersen, F., Pedersen, S. S., Fomsgaard, A., Koch, C., Høiby, N. Immunoglobulin allotypes and IgG sublcass antibody response toPseudomonas aeruginosa antigens in chronically infected cystic fibrosis patients. Clin. Exp. Immunol. 90 (1992) 209–214.Google Scholar
  8. 8.
    Polgar, G., Promadhat, V. Pulmonary function testing in children. Techniques and standards. W. B. Saunders, Philadelphia 1971, 88–107, 178–180.Google Scholar
  9. 9.
    Freudenberg, M. A., Fomsgaard, A., Mitov, I., Galanos, C. ELISA for antibodies to lipid A, lipopolysaccharide and other hydrophobic antigens. Infection 17 (1989) 322–328.Google Scholar
  10. 10.
    Westphal, O., Jann, K. Bacterial lipopolysaccharides: extraction with phenol-water and further applications of the procedure. Methods Carbohydr. Chem. 5 (1965) 83–91.Google Scholar
  11. 11.
    Ojeniyi, B., Høiby, N., Rosdahl, V. T. Prevalence and persistence of polyagglutinablePseudomonas aeruginosa in isolates from cystic fibrosis patients. APMIS 99 (1991) 187–195.Google Scholar
  12. 12.
    Fomsgaard, A., Shand, G. H., Freudenberg, M. A., Galanos, C., Conrad, R. S., Kronborg, G., Høiby, N. Antibodies from chronically infected cystic fibrosis patients react with lipopolysaccharide extracted by new micro-methods from all serotypes ofPseudomonas aeruginosa. APMIS 101 (1993) 101–112.Google Scholar
  13. 13.
    Kronborg, G., Fomsgaard, A., Shand, G. H., Høiby, N. Determination of the components of immune complexes madein vitro with antigens derived fromPseudomonas aeruginosa. J. Immunol. Methods. 122 (1989) 51–57.Google Scholar
  14. 14.
    Kronborg, G., Fomsgaard, A., Shand, G. H., Lanng, S., Hansen, M. B., Pressler, T., Høiby, N. TNF-α and immune complexes in sputum and serum from patients with cystic fibrosis and chronicPseudomonas aeruginosa lung infection. Immunol. & Infect. Dis. 2. (1992) 171–177.Google Scholar
  15. 15.
    Galanos, C., Rietschel, E. T., Lüderitz, O., Westphal, O. Interaction of lipopolysaccharide and lipid A with complement. Eur. J. Biochem. 19 (1971) 143–152.Google Scholar
  16. 16.
    Hancock, R. E., Mutharia, L. C., Chan, L., Darveau, R. P., Speert, D. P., Pier, G. B. Pseudomonas aeruginosa isolates from patients with cystic fibrosis: a class of serum-sensitive, nontypable strains deficient in lipopolysaccharide O side chains. Infect. Immun. 42 (1983) 170–177.Google Scholar
  17. 17.
    Fomsgaard, A., Conrad, R. S., Galanos, C., Shand, G. H., Høiby, N. Comparative immunochemistry of lipopolysaccharides from typable and polyagglutinablePseudomonas aeruginosa strains isolated from patients with cystic fibrosis. J. Clin. Microbiol. 26 (1988) 821–826.Google Scholar
  18. 18.
    Marget, W. Lipoid A — Antikörpertiter beim Menschen. Infection 15 (1987) 142–145.Google Scholar
  19. 19.
    Pressler, T., Pedersen, S. S., Espersen, F., Høiby, N., Koch, C. IgG subclass antibody responses to alginate fromPseudomonas aeruginosa in patients with cystic fibrosis and chronicP. aeruginosa infection. Ped. Pulm. 14 (1992) 44–51.Google Scholar
  20. 20.
    Ziegler, E. J., Fisher, Jr., C. J., Sprung, C. L., Straube, R. C., Sadoff, J. C., Foulke, G. E., Wortel, C. H., Fink, M. P., Dellinger, R. P., Teng, N. N. H., Allen, I. E., Berger, H. J., Knatterud, G. L., LoBuglio, A. F., Smith, C. R., andthe HA-1A Sepsis Study Group Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, doubleblind, placebo-controlled trial. N. Engl. J. Med. 324 (1991) 429–436.Google Scholar
  21. 21.
    Hornick, D. B., Fick, Jr., R. B. The immunoglobulin G subclass composition of immune complexes in cystic fibrosis. J. Clin. Invest. 86 (1990) 1285–1292.Google Scholar
  22. 22.
    Kronborg, G., Hansen, M. B., Svenson, M. Fomsgaard, A., Høiby, N., Bendtzen, K. Cytokines in sputum and serum from patients with cystic fibrosis and chronicPseudomonas aeruginosa lung infection as markers of destructive inflammation in the lungs. Ped. Pulm 15 (1993) 292–297.Google Scholar
  23. 23.
    Arend, W. P., Joslin, F. G., Massoni, R. J. Effects of immune complexes on production by human monocytes of interleukin 1 or an interleukin 1 inhibitor. J. Immunol. 134 (1985) 3868–3875.Google Scholar

Copyright information

© MMV Medizin Verlag GmbH München 1993

Authors and Affiliations

  • Gitte Kronborg
    • 1
  • T. Pressler
    • 1
  • A. Fomsgaard
    • 1
  • C. Koch
    • 1
  • N. Høiby
    • 1
  1. 1.Dept. of Clinical Microbiology, Dept. of Pediatrics and The Danish CF Center at RigshospitaletCopenhagenDenmark

Personalised recommendations